Updated assessment of risks and benefits of dolutegravir...

  • Main
  • 2020 / 2
  • Updated assessment of risks and benefits of dolutegravir...

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines

Phillips, Andrew N, Bansi-Matharu, Loveleen, Venter, Francois, Havlir, Diane, Pozniak, Anton, Kuritzkes, Daniel R, Wensing, Annemarie, Lundgren, Jens D, Pillay, Deenan, Mellors, John, Cambiano, Valent
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
The Lancet HIV
DOI:
10.1016/S2352-3018(19)30400-X
Date:
February, 2020
File:
PDF, 108 KB
2020
Conversion to is in progress
Conversion to is failed